6 Literaturverzeichnis

1. **Hodgkin T. On some morbid appearances of the absorbed glands and spleen. Med Chir Trans 1832;17:68.**

2. **Wilks Sir S. *Cases of enlargement of the lymphoic glands and spleen, (or Hodgkin`s disease), with remarks* . Guy`s Hosp Rep 1865;11:56-67.**

3. **Reed DM. *On the pathological changes in Hodgkin`s disease, with special reference to its relationship to tuberculosis.* Johns Hosp Rep 1902;10:133-196.**

4. **Sternberg C. *Über eine eigenartig unter dem Bilde einer Pseudoleukämie verlaufende Tuberculose des lymphatischen Apparates.* Zschr Heilk 1898;19:21-90.**

5. **Hartge P DSFJ. Hodgkin`s and non-Hodgkin`s lymphomas. In: Doll R FJMC, ed. Trends in Cancer Incidence and Mortality Cancer Surveys. Cold Spring: Cold Spring Harbor Press; 1994:423-453.**

6. **Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1083.**

7. **Attie E. [Proposal of an international classification of Hodgkin's disease]. Rev.Med.Moyen.Orient. 1966;23:200-204.**

8. **Haluska FG, Brufsky AM, Canellos GP. The cellular biology of the Reed-Sternberg cell [see comments]. Blood 1994;84:1005-1019.**

9. **Pinkus GS, Said JW. Hodgkin's disease, lymphocyte predominance type, nodular--further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker. Am.J.Pathol. 1988;133:211-217.**

10. Stein H GJLHea. Immunohistological classification of .... In: Ford RJ FLHFea, ed. MD Anderson Clinical Conference on Cancer: New perspectives in Human Leukemia. Vol 27. New York: Raven Press; 1984:35-47.

11. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk.Lymphoma 1992;8:283-313.

12. Marafioti T, Hummel M, Foss HD et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-1450.

13. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J.Exp.Med. 1996;184:1495-1505.

14. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994;84:1361-1392.

15. Lukes RJ. Criteria for involvement of lymph node, bone marrow, spleen, and liver in Hodgkin's disease. Cancer Res. 1971;31:1755-1767.

16. Buttler JJ. The natural history of hodgkin`s desease and its classification. In: Rebuck JW BGAM, ed. The reticuloendothelial system: International Academy of Pathology Monograph No16. Baltimore: Williams and Wilkins; 1975:184-212.

17. Chittal SM, Caveriviere P, Schwarting R et al. Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel. Am.J.Surg.Pathol. 1988;12:9-21.

18. Hsu SM, Jaffe ES. Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am.J.Clin.Pathol. 1984;82:29-32.

19. Pinkus GS, Thomas P, Said JW. Leu-M1--a marker for Reed-Sternberg cells in Hodgkin's disease. An immunoperoxidase study of paraffin-embedded tissues. Am.J.Pathol. 1985;119:244-252.

20. Strauchen JA, Dimitriu-Bona A. Immunopathology of Hodgkin's disease. Characterization of Reed- Sternberg cells with monoclonal antibodies. Am.J.Pathol. 1986;123:293-300.

21. Casey TT, Olson SJ, Cousar JB, Collins RD. Immunophenotypes of Reed-Sternberg cells: a study of 19 cases of Hodgkin's disease in plastic-embedded sections. Blood 1989;74:2624-2628.

22. Ree HJ, Neiman RS, Martin AW, Dallenbach F, Stein H. Paraffin section markers for Reed-Sternberg cells. A comparative study of peanut agglutinin, Leu-M1, LN-2, and Ber-H2. Cancer 1989;63:2030-2036.

23. Stein H GJFB. phenotypic and genotypic markers in malignant lymphomas: Cellular origin of Hodgkin and Sternberg-Reed cells and implications for the classification of T-cell and B-cell lymphoma. In: Seifert G HKGF, ed. Pathology of Cell Receptors and Tumor Markers. Stuttgart 1987:121-144.

24. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg- Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:65-67.

25. Stein H, Gerdes J, Schwab U et al. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int.J.Cancer 1982;30:445-459.

26. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-858.

27. Kuppers R, Zhao M, Hansmann ML, Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J. 1993;12:4955-4967.

28. Seitz V, Hummel M, Marafioti T et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 2000;95:3020-3024.

29. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-716.

30. Bargou RC, Leng C, Krappmann D et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340-4347.

31. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu.Rev.Cell Biol. 1994;10:405-455.

32. Bours V, Franzoso G, Brown K et al. Lymphocyte activation and the family of NF-kappa B transcription factor complexes. Curr.Top.Microbiol.Immunol. 1992;182:411-420.

33. Bours V, Burd PR, Brown K et al. A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol.Cell Biol. 1992;12:685-695.

34. Ryseck RP, Bull P, Takamiya M et al. RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol.Cell Biol. 1992;12:674-684.

35. Ip YT, Reach M, Engstrom Y et al. Dif, a dorsal-related gene that mediates an immune response in Drosophila. Cell 1993;75:753-763.

36. Steward R. Dorsal, an embryonic polarity gene in Drosophila, is homologous to the vertebrate proto-oncogene, c-rel. Science 1987;238:692-694.

37. Rice NR, MacKichan ML, Israel A. The precursor of NF-kappa B p50 has I kappa B-like functions. Cell 1992;71:243-253.

38. Logeat F, Israel N, Ten R et al. Inhibition of transcription factors belonging to the rel/NF-kappa B family by a transdominant negative mutant. EMBO J. 1991;10:1827-1832.

39. Bressler P, Brown K, Timmer W et al. Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants. J.Virol. 1993;67:288-293.

40. Latimer M, Ernst MK, Dunn LL, Drutskaya M, Rice NR. The N-terminal domain of IkappaB alpha masks the nuclear localization signal(s) of p50 and c-Rel homodimers. Mol.Cell Biol. 1998;18:2640-2649.

41. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-6866.

42. Miyamoto S, Schmitt MJ, Verma IM. Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc.Natl.Acad.Sci.U.S.A 1994;91:5056-5060.

43. **Liou HC, Sha WC, Scott ML, Baltimore D. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol.Cell Biol. 1994;14:5349-5359.**

44. **Houldsworth J, Mathew S, Rao PH et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996;87:25-29.**

45. **Liptay S, Schmid RM, Perkins ND et al. Related subunits of NF-kappa B map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2. Genomics 1992;13:287-292.**

46. **Neri A, Chang CC, Lombardi L et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 1991;67:1075-1087.**

47. **Maxwell SA, Mukhopadhyay T. A novel NF-kappa B p65 spliced transcript lacking exons 6 and 7 in a non-small cell lung carcinoma cell line. Gene 1995;166:339-340.**

48. **Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 1995;11:999-1003.**

49. **Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF- kap. Biochem.Pharmacol. 1994;47:145-149.**

50. **Bargou RC, Emmerich F, Krappmann D et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J.Clin.Invest 1997;100:2961-2969.**

51. **Tran K, Merika M, Thanos D. Distinct functional properties of IkappaB alpha and IkappaB beta. Mol.Cell Biol. 1997;17:5386-5399.**

52. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 1993;259:1912-1915.

53. Chiao PJ, Miyamoto S, Verma IM. Autoregulation of I kappa B alpha activity. Proc.Natl.Acad.Sci.U.S.A. 1994;91:28-32.

54. Sachdev S, Hoffmann A, Hannink M. Nuclear localization of IkappaB alpha is mediated by the second ankyrin repeat: the IkappaB alpha ankyrin repeats define a novel class of cis- acting nuclear import sequences. Mol.Cell Biol. 1998;18:2524-2534.

55. Arenzana-Seisdedos F, Thompson J, Rodriguez MS et al. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF- kappa B. Mol.Cell Biol. 1995;15:2689-2696.

56. Ito CY, Adey N, Bautch VL, Baldwin AS, Jr. Structure and evolution of the human IKBA gene. Genomics 1995;29:490-495.

57. Chiao PJ, Miyamoto S, Verma IM. Autoregulation of I kappa B alpha activity. Proc.Natl.Acad.Sci.U.S.A 1994;91:28-32.

58. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997;91:243-252.

59. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB [see comments]. Nature 1997;388:548-554.

60. **Mercurio F, Zhu H, Murray BW et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF- kappaB activation [see comments]. Science 1997;278:860-866.**

61. **Mercurio F, Murray BW, Shevchenko A et al. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol.Cell Biol. 1999;19:1526-1538.**

62. **Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex [see comments]. Nature 1998;395:297-300.**

63. **Yaron A, Gonen H, Alkalay I et al. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. EMBO J. 1997;16:6486-6494.**

64. **Beauparlant P, Lin R, Hiscott J. The role of the C-terminal domain of I kappa B alpha in protein degradation and stabilization. J.Biol.Chem. 1996;271:10690-10696.**

65. **Meisner H, Czech MP. Phosphorylation of transcriptional factors and cell-cycle-dependent proteins by casein kinase II. Curr.Opin.Cell Biol. 1991;3:474-483.**

66. **Lin R, Beauparlant P, Makris C, Meloche S, Hiscott J. Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. Mol.Cell Biol. 1996;16:1401-1409.**

67. **Barroga CF, Stevenson JK, Schwarz EM, Verma IM. Constitutive phosphorylation of I kappa B alpha by casein kinase II. Proc.Natl.Acad.Sci.U.S.A. 1995;92:7637-7641.**

68. Haskill S, Beg AA, Tompkins SM et al. Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell 1991;65:1281-1289.

69. Angerer L.M. Demonstration of tissue-specific gene expression by in situ hybridization. Methods Enzymol 1987;152:649-661.

70. Milani S, Herbst H, Schuppan D, Hahn EG, Stein H. In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. Hepatology 1989;10:84-92.

71. Cordell JL, Falini B, Erber WN et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J.Histochem.Cytochem. 1984;32:219-229.

72. Kuppers R, Hansmann ML, Rajewsky K. Clonality and germinal centre B-cell derivation of Hodgkin/Reed- Sternberg cells in Hodgkin's disease. Ann.Oncol. 1998;9 Suppl 5:S17-S20.

73. Montesinos-Rongen M, Roers A, Kuppers R, Rajewsky K, Hansmann ML. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 1999;94:1755-1760.

74. Hummel M, Anagnostopoulos I, Korbjuhn P, Stein H. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high- grade types. J.Pathol. 1995;175:263-271.

75. Krappmann D, Emmerich F, Kordes U et al. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999;18:943-953.

76. Wood KM, Roff M, Hay RT. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene 1998;16:2131-2139.

77. Luque I, Gelinas C. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin.Cancer Biol. 1997;8:103-111.

78. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-6947.

79. Sonenshein GE. Rel/NF-kappa B transcription factors and the control of apoptosis. Semin.Cancer Biol. 1997;8:113-119.

80. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996;381:751-758.

81. Beg AA, Baldwin AS, Jr. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev. 1993;7:2064-2070.

82. Beg AA, Finco TS, Nantermet PV, Baldwin ASJ. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol.Cell Biol. 1993;13:3301-3310.

83. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc.Natl.Acad.Sci.U.S.A. 1993;90:2532-2536.

84. Sun SC, Ganchi PA, Beraud C, Ballard DW, Greene WC. Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc.Natl.Acad.Sci.U.S.A. 1994;91:1346-1350.

85. Beg AA, Ruben SM, Scheinman RI et al. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention [published erratum appears in Genes Dev 1992 Dec;6(12B):2664-5]. Genes Dev. 1992;6:1899-1913.

86. Ganchi PA, Sun SC, Greene WC, Ballard DW. I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol.Biol.Cell 1992;3:1339-1352.

87. Beg AA, Sha WC, Bronson RT, Baltimore D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev. 1995;9:2736-2746.

88. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999;18:3063-3070.

89. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk.Lymphoma 1993;9:1-25.

90. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat.Med. 1999;5:412-417.

91. Kawamura I, Morishita R, Tomita N et al. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther. 1999;6:91-97.

92. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin.Oncol. 2001;28:626-633.

93. Chandra J, Niemer I, Gilbreath J et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998;92:4220-4229.

94. Higgins KA, Perez JR, Coleman TA et al. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc.Natl.Acad.Sci.U.S.A 1993;90:9901-9905.

95. Annunziata CM, Safiran YJ, Irving SG, Kasid UN, Cossman J. Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. Blood 2000;96:2841-2848.